Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
Love Douglas reported acquisition or exercise transactions in this Form 4 filing.
Annexon, Inc. director and President & CEO Douglas Love reported receiving a grant of stock options covering 1,250,000 shares of the company’s stock. These are derivative securities, reflecting an equity incentive award rather than an open-market share purchase or sale.
According to the vesting terms, 1/48th of the option shares vest on each monthly anniversary starting on February 19, 2026, so the award becomes fully vested and exercisable on the fourth anniversary of that date. Vesting depends on Mr. Love’s continuous service with Annexon on each vesting date.
Annexon, Inc. reported that its Chief Medical Officer, Jamie Dananberg, received new equity awards on February 19, 2026. The awards include a stock option covering 225,000 shares at an exercise price of $0.00 per share and a grant of 56,250 shares of common stock in the form of restricted stock units (RSUs).
According to the filing, 1/48 of the option shares vest monthly starting from February 19, 2026, becoming fully vested on the fourth anniversary, subject to continued service. For the RSUs, one-third vests each year on February 19, with the first third vesting on February 19, 2027, also conditioned on continuous service. Following these grants, Dananberg directly owns 129,402 shares of common stock.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported equity awards consisting of stock options and restricted stock units. He was granted 250,000 stock options at an exercise price of $0.00 per share, with 1/48th of the option vesting monthly from February 19, 2026 so that all options vest over four years, subject to continued service. He also received 62,500 RSUs, each convertible into one share of common stock, with 1/3 vesting each year on February 19 starting in 2027, also conditioned on continued service.
Annexon, Inc. reported that EVP & Chief Scientific Officer Dean Richard Artis acquired equity awards on
Annexon, Inc. reported that EVP & Chief Innovation Officer Ted Yednock acquired new equity awards. He received a stock option for 250,000 shares of common stock at an exercise price of $0.00 per share, vesting in equal monthly installments over four years starting on
He also received 62,500 restricted stock units, each RSU converting into one share of common stock upon vesting. One-third of these RSUs vest annually on
Annexon, Inc. reported that EVP and Chief Financial Officer Jennifer Lew received equity awards on February 19, 2026. She was granted a stock option for 250,000 shares of common stock at an exercise price of $0.00 per share, vesting in equal monthly installments over four years starting from February 19, 2026. She also received 62,500 shares of common stock in the form of restricted stock units, each RSU representing one share upon vesting. One-third of these RSUs vest on February 19 of each year, with the first third vesting on February 19, 2027, subject to her continued service with the company.
Annexon, Inc. chief medical officer Jamie Dananberg reported an open-market sale of 5,290 shares of common stock at a weighted average price of $5.10 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this tax-related sale, Dananberg directly holds 73,152 Annexon shares.
Annexon, Inc. Executive Vice President and Chief Financial Officer Jennifer Lew reported an open-market sale of 7,851 shares of common stock at a weighted average price of $5.11 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After this transaction, she directly holds 113,765 shares of Annexon common stock.
Annexon, Inc. executive reports tax-related stock sale
Annexon, Inc. executive Dean Richard Artis, EVP & Chief Scientific Officer, reported an open-market sale of 5,290 shares of common stock at a weighted average price of $5.10 per share. According to the filing, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, Artis beneficially owns 123,487 shares of Annexon common stock directly. The sale was executed in multiple trades within a price range of $4.925 to $5.155 per share.
Annexon, Inc. executive Ted Yednock reported an open-market sale of 7,857 shares of common stock on February 18, 2026, at a weighted average price of $5.11 per share. The filing notes the shares were sold to cover tax withholding obligations tied to vesting restricted stock units.
After this transaction, Yednock directly owned 97,227 Annexon shares. The sale was executed in multiple trades at prices ranging from $4.925 to $5.17, with the reported price reflecting the weighted average across those trades.